Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Mikus

Showing results (91-100 of 194) with videos related to

Pageof 20
Sort By:
Danish Medical Journal|April 30, 2016
The CYTONOX trialChristina Gade, Gerd Mikus, Hanne Rolighed Christensen, et al.
European Journal of Clinical Pharmacology|September 24, 2008
High absolute bioavailability of methylene blue given as an aqueous oral formulationIngeborg Walter-Sack, Jens Rengelshausen, Heike Oberwittler, et al.
Journal of Clinical Pharmacology|August 14, 2013
Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activityFelicitas Stoll, Jürgen Burhenne, Berthold Lausecker, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 9, 2022
A versatile high-performance LC-MS/MS assay for the quantification of voriconazole and its N-oxide metabolite in small sample volumes of multiple human matrices for biomedical applicationsJosefine Schulz, Robin Michelet, Jan F Joseph, et al.
Clinical Pharmacology and Therapeutics|July 2, 2004
Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteersReinhard Ding, Yorki Tayrouz, Klaus-Dieter Riedel, et al.
Scientific Reports|October 12, 2019
Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patientsMarcus J P Geist, Victoria C Ziesenitz, Hubert J Bardenheuer, et al.
European Journal of Clinical Pharmacology|June 11, 2013
Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1Christoph Markert, Regina Hellwig, Jürgen Burhenne, et al.
Cancers|July 14, 2023
Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical ChallengesJason van Leuven, Simon Evans, Ganessan Kichenadasse, et al.
Analytical and Bioanalytical Chemistry|January 19, 2012
Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometryJürgen Burhenne, Birte Halama, Monika Maurer, et al.
Clinical Pharmacokinetics|February 16, 2020
Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I TrialManuela Vay, Marleen Julia Meyer, Antje Blank, et al.
Pageof 20

Showing results (91-100 of 194) with videos related to

Sort By:
Pageof 20
Danish Medical Journal|April 30, 2016
The CYTONOX trialChristina Gade, Gerd Mikus, Hanne Rolighed Christensen, et al.
European Journal of Clinical Pharmacology|September 24, 2008
High absolute bioavailability of methylene blue given as an aqueous oral formulationIngeborg Walter-Sack, Jens Rengelshausen, Heike Oberwittler, et al.
Journal of Clinical Pharmacology|August 14, 2013
Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activityFelicitas Stoll, Jürgen Burhenne, Berthold Lausecker, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 9, 2022
A versatile high-performance LC-MS/MS assay for the quantification of voriconazole and its N-oxide metabolite in small sample volumes of multiple human matrices for biomedical applicationsJosefine Schulz, Robin Michelet, Jan F Joseph, et al.
Clinical Pharmacology and Therapeutics|July 2, 2004
Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteersReinhard Ding, Yorki Tayrouz, Klaus-Dieter Riedel, et al.
Scientific Reports|October 12, 2019
Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patientsMarcus J P Geist, Victoria C Ziesenitz, Hubert J Bardenheuer, et al.
European Journal of Clinical Pharmacology|June 11, 2013
Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1Christoph Markert, Regina Hellwig, Jürgen Burhenne, et al.
Cancers|July 14, 2023
Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical ChallengesJason van Leuven, Simon Evans, Ganessan Kichenadasse, et al.
Analytical and Bioanalytical Chemistry|January 19, 2012
Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometryJürgen Burhenne, Birte Halama, Monika Maurer, et al.
Clinical Pharmacokinetics|February 16, 2020
Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I TrialManuela Vay, Marleen Julia Meyer, Antje Blank, et al.
Pageof 20